LUPIN - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.7
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established around 2,050 ₹ – utilizing the lower channel support – or slightly above at 2,180 ₹, based on momentum and volume. An exit strategy would involve setting a stop-loss order at approximately 1,980 ₹ to protect against downside risk. The overall picture suggests a cautiously bullish outlook with an emphasis on monitoring volume and potential support levels before committing to a larger position.
✅ Positive
The price is currently trading within a defined channel between approximately 2,050 ₹ and 2,250 ₹. Volume remains consistently high above the one-week average, suggesting sustained interest in the stock. Additionally, the RSI of 35.1 indicates that the stock is relatively undervalued compared to its historical momentum, potentially signaling a buying opportunity.
⚠️ Limitation
Despite the high volume, the MACD (-55.5) suggests a bearish divergence between price and momentum, which could indicate weakening bullish sentiment. The current P/E ratio of 14.9 is below the industry average of 34.8 – this reflects undervaluation, but also may suggest limited growth expectations that are priced in.
📉 Company Negative News
Recent news highlights an FDA Form 483 with observations for Lupin's Somerset facility, potentially raising concerns about regulatory hurdles and future drug approvals, although this is not reflected directly in price action yet. Another headline reports continued downside pressure on the stock, implying further selling pressure is likely.
📈 Company Positive News
The rise of 2.04% in share price due to valuation and peer activity suggests positive sentiment within the sector regarding Lupin's financial performance; also there are indications that analysts are maintaining a 'hold' position - this does not necessarily signal bullishness, but provides an indication for potential support level.
🏭 Industry
The pharmaceutical industry is currently characterized by moderate growth driven largely by generic drug demand and innovation in specific therapeutic areas. Sector PE ratios remain elevated due to the sustained growth rates observed by many larger pharmaceutical players. Lupin’s position as a key player within complex generics presents both opportunities and challenges related to regulatory approvals, pricing pressures, and competition.